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Abstract: Amyloidosis is a rare heterogeneous group of systemic disorders, which result due to extra cellular deposition 
of an insoluble, amorphous, eosinophilic, substance known as amyloid. The disease is often characterized by a 
restrictive cardiomyopathy with a poor prognosis and survival. The treatment of cardiac amyloidosis depends on the 
underlying etiology. However, the diagnosis of the type of cardiac amyloidosis is not always straightforward. We present 
here a case of cardiac amyloidosis and we discuss the different forms.  
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INTRODUCTION 
Amyloidosis is a rare systemic disease and heart is 
involved in some cases. It refers to the extra-cellular 
tissue deposition of fibrils composed of low molecular 
weight subunits. More than 20 distinct low molecular 
weight proteins are recognized to form amyloid fibrils. 
These fibrils have a specific configuration and can be 
identified on biopsy specimens both by their 
characteristic appearance on electron microscopy, and 
by their ability to bind Congo red [1]. 
Cardiac involvement is seen in approximately 60 
percent of patients and is typically characterized by 
symptoms and signs of restrictive cardiomyopathy. 
Therapeutic approach depends on the type of 
amyloidosis, but it is known the poor prognosis of 
cardiac amyloidosis [2]. 
We present a patient with presumed cardiac 
amyloidosis and we review the different forms.  
CASE DESCRIPTION  
n 83 year-old Caucasian man was admitted to our 
department with dyspnea associated with chest 
discomfort without the characteristics of angina, fatigue 
and lower limb edema. The patient had no family 
history of cardiovascular disease and the medical 
history showcased dementia. His personal story begins 
two months ago, where he was hospitalized due to 
peptic ulcer and in the context of laboratory 
examinations was found pleural effusion (transudate). 
He was discharged with a recommendation for 
conducting echocardiogram on a regular basis while 
the medication included furosemide, carvedilol and 
proton-pump inhibitors (PPIs). 
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Upon discharge, on physical examination he was ill-
appearing, afebrile, with a blood pressure of 110/70 
and heart rate of 80bpm. He was breathing at a rate of 
22 breaths per minute and his oxygen saturation was 
96% on FiO2 21%. His jugular venous was slightly 
distended and a positive hepatojugular reflux was 
present. Cardiac exam revealed a regular rate and 
rhythm, with systolic murmur audible at the apex of the 
heart. On lung exam, he had bilateral rales at the 
bases and his abdomen was slightly distended. 
Table 1: Laboratory Values on Admission 
Exams Value 
GLU 92mg/dl 
UREA 55mg/dl 
CREA 1.39 mg/dl 
Na 136 mmol/dl 
K 4.64 mmol/dl 
AST 36 IU/L 
ALT 30 IU/L 
ALP 82 IU/L 
LDH 583 IU/L 
CK 63 IU/L 
CKMB 56 IU/L 
TROPONINE-T High Sensitive 67.97 pg/ml 
CRP 8.7 mg/dl 
TKE 107 
WBC 10.82 
NEU 73.7% 
LYM 17.2% 
HCT 40.1 
HGB 13.6 g/dl 
PLT 547103/L 
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Laboratory values on admission are shown in Table 
1. The ECG revealed sinus rhythm, with ventricular rate 
74 bpm, first degree AV block, low QRS voltage in 
precordial and lower leads and a pseudo-infarct pattern 
without signs of left ventricular hypertrophy [Figure 1]. 
The chest X-ray on admission showed minimal pleural 
effusion on the right base [Figure 3, 4].  
 
Figure 2: Face X- ray. Pleural effusion on the right base. 
Two-dimensional trans-thoracic echocardiogram 
revealed a small left ventricular cavity with evidence of 
left and right ventricular hypertrophy. The left 
ventricular ejection fraction was 50%. Both the left and 
right atria were moderately dilated. Four-chamber 
views of the ventricles and atria suggested the 
possibility of a restrictive cardiomyopathy [Figure 4]. 
There was reported a moderate mitral regurgitation 
[Figure 5]. Right ventricular systolic pressure was 
estimated at 30 mmHg while a severe diastolic 
dysfunction was present (E/E>13) [Figure 6]. 
 
Figure 4: Four chambers view – “sparkle” myocardium. 
 
Figure 5: Moderate mitral regurgitation. 
 
Figure 1: ECG. First degree AV block, low QRS voltage in limb leads, Q wave in inferior leads and in V1-V3. 
 
Figure 3: Profile X-ray.  
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Taking into consideration of the severe diastolic 
dysfunction of left ventricular, the “sparkle” myocardium 
in two-dimensional trans-thoracic echocardiogram 
[Figure 7], the elevated values of three digiterythrocyte 
sedimentation rate and a pseudo-infarctpattern in the 
ECG, we further examine the patient byconducting a 
subcutaneous fat pad biopsy and a bonemarrow 
biopsy. 
 
Figure 7: Two chambers view– “sparkle” myocardium.  
Bone marrow biopsy was performed on the fifth 
hospital day and amyloid deposition proved positive 
associated with myeloma multiple. Immunohisto 
chemical examination with antibodies against the 
antigens CD20, CD3, CD138, CD56, of light and heavy 
chains of immunoglobulins showed plasma cells 
mature type CD138+ CD56+/, cyclin D1, with lambda 
light chain, which are developed by forming tendency 
summations. The cell infiltrate that was estimated 
account at 12-15%. 
A subcutaneous fat pad biopsy, was performed on 
the sixth hospital day, and it was positive for detection 
of amyloid in the vessel wall, and diffusible in the tissue 
(Congo red positive). 
The patient was treated with cortisone (prednisone) 
under continuous hematological monitoring. 
DISCUSSION 
myloidosis is a rare systemic disease 
characterized by amyloid deposition in different organs 
and tissues. There are several types of amyloidosis: 
primary amyloidosis (AL), secondary amyloidosis (AA), 
familial amyloidosis, senile systemic amyloidosis and 
Beta-2 Micro globulin Amyloidosis (Abeta2m). 
TYPES OF AMYLOIDOSIS 
The most frequent types of amyloidosis are the AL 
(primary) and AA (secondary) types. 
AL Amyloidosis 
Deposition of immunoglobuline light chains (kappa 
or lambda) indicates this type of amyloidosis. 
Monoclonal immunoglobulin light chain, is produced in 
the bone marrow, and usually is found in the blood or 
urine. AL amyloidosis can occur alone, in association 
with multiple myeloma or, much less often, 
Waldenström’s macroglobulinemia or non-Hodgkin 
lymphoma. 
AL amyloidosis, can appear with a variety of 
symptoms or signs, including heavy proteinuria, 
edema, hepatosplenomegaly, and unexplained heart 
failure. 
It is an uncommon systemic disorder, and in United 
States, the occurrence appears to be 6 – 10 cases per 
million [1].  
There is a male predominance in this disorder and 
the median age of diagnosis is at 64 years of age [2]. 
 
Figure 6: Severe diastolic dysfunction. 
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The prognosis for patients with AL amyloidosis is, 
poor. Median survival is 13 months without treatment, 
and can be extended to 17 months with cyclic oral 
melphalan and prednisone therapy [3].  
Only 5% of patients survive for more than 10 years 
[4].  
The 85% of patients with AL amyloidosis will have 
circulating monoclonal proteins in serum or urine. As a 
result, patients with a presumed cardiac amyloid 
infiltration, but no evidence of a monoclonal gammo 
pathy, will require an endomyocardial biopsy [5, 6].  
The diagnosis of primary AL amyloidosis, is not 
certain, considering that up to 3% of patients over the 
age of 70, have a monoclonal gammopathy of 
undetermined significance (MGUS) [7].  
The clinical presentations depend on the organs 
affected, while in many patients it is possible to identify 
a dominant organ affected. Renal involvement occurs, 
in approximately 70 percent of the cases with 
asymptomatic proteinuria as a chance finding. Cardiac 
involvement leads to systolic and diastolic dysfunction, 
with symptoms of heart failure [8]. In addition, there can 
be angina or infraction, due to accumulation of 
amyloide in coronary arteries. Peripheral neuropathy is 
present in 20% of patients with AL. Frequently are 
present, paresthesia and findings of orthostatic 
hypotension. Purpura and other skin manifestations 
(ecchymoses, subcutaneous nodules), are highly 
characteristic of AL amyloidosis [9]. 
In general, therapy involves the administration of 
chemotherapy and/or autologous stem cell 
transplantation (ASCT). The most common 
chemotherapy, regimens used, include melphalan plus 
dexamethasone, or bortezomib-based regimens, such 
as bortezomib, cyclophosphamide, and dexametha 
sone. ASCT involves administration of high-dose 
melphalan, followed by stem cell rescue. Patients with 
symptoms of heart failure, are excluded of stem cell 
transplantation. 
In immunoglobulin light chain (AL) amyloidosis, 
amyloid fibril deposits, derived from immunoglobulin 
light chains, produced by a clonal plasma cell 
dyscrasia, accumulate in tissues and damage vital 
organs. Treatment regimens used in multiple myeloma 
can be effective in AL amyloidosis; however, patients 
with this disease, often tolerate these regimens poorly, 
because of multisystem organ dysfunction. 
Thalidomide and lenalidomide as a single agent, and in 
combination with dexamethasone, have both been 
shown to be effective in myeloma.  
In newly diagnosed patients, who are not 
candidates for high-dose chemotherapy with peripheral 
blood stem cell transplantation, the combination of 
lenalidomide and dexamethasone, may be an option as 
either first, or second-line therapy. For patients who 
have relapsed after other treatments, the lenalidomide 
and dexamethasone combination, is a viable choice 
[10]. 
Stem cell transplantation (STC), for primary 
systemic amyloidosis, is applicable to a minority of 
patients, such as those with limited organ disease, and 
no significant cardiac involvement. Response rates with 
SCT appear to be higher, than those seen in patients 
treated with traditional melphalan and prednisone. 
Morbidity and mortality are clearly higher, than in 
patients with multiple myeloma or other hematologic 
malignancies undergoing autologous SCT. An 
unusually high rate of significant gastrointestinal tract 
hemorrhage, and cardiac complications including 
arrhythmias, are prevalent. SCT for AL will remain 
controversial, until there is either a multicenter phase 3 
trial, comparing it to standard therapy in newly 
diagnosed patients, or a multicenter phase 2 trial using 
a risk-adapted approach, showing reduced treatment-
related mortality. We anticipate that, improved patient 
selection, peri-transplantation management, and 
adoption of a risk-adapted approach to melphalan 
dosing based on organ involvement, and age, will 
accelerate the acquisition of the expertise needed for 
the conduct of multicenter SCT trials, and will enhance 
the impetus for early diagnosis and timely treatment of 
AL.  
AA Amyloidosis 
AA amyloidosis, the most common form in 
developing countries may complicate chronic diseases 
such as rheumatoid arthritis (RA), spondyloarthropathy, 
or inflammatory bowel disease, chronic infections, or 
periodic fever syndromes [11]. As a result of chronic 
inflammation, serum amyloid A (protein in acute 
phase), composes the fibrils. AA amyloidosis at the 
beginning affects the kidneys, but other organs can be 
involved. 
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Familial Amyloidosis 
Deposition of transthyretin in myocardium and other 
tissues, has been referred to as Systemic Senile 
Amyloidosis (SSA) [12]. A mutation in the transthyretin 
(TTR) gene that produces abnormal transthyretin 
protein, is typical in familial amyloiodosis. The 
abnormal TTR protein, accumulates as amyloid fibrils: 
thus, it is termed ATTR amyloidosis. Symptoms of 
disease are usually, neuropathy and cardiomyopathy, 
and occur in mid to late life. Treatment is a liver 
transplant; however, newer treatments with targeted 
inhibitors, are in clinical trials. Compared with patients 
with AL amyloidosis, those with the senile systemic 
disease, survive longer (75 versus 11 months), despite 
having ventricular free wall and septal thickening, due 
to amyloid accumulations [13].  
However, less common than AL amyloidosis, is a 
familial form associated with a point mutation in the 
transthyretin molecule (ATTR). The clinical 
presentation is usually polyneuropathy and/or 
cardiomyopathy, and more than 100 variant 
transthyretin proteins with single amino acid 
substitutions, have been described, most of which are 
amyloidogenic. Patients with ATTR amyloidosis who 
have cardiac involvement, may have an 
echocardiographic appearance in distinguishable from 
patients with AL cardiac amyloidosis but with a 
significantly longer survival time. A mutation in ATTR is 
not a prerequisite for the formation of transthyretin- 
associated amyloid fibrils. In elderly patients, wild-type 
transthyretin, may be come structurally unstable, 
resulting in the development of misfolded intermediates 
that ultimately aggregate and precipitate as amyloid 
[14]. These fibrils form in many different organs, but 
they have a predisposition for the heart [15]. Although 
cardiac deposits of wild-type transthyretin amyloid are 
not uncommonly found in small amounts at autopsy in 
elderly patients who had few or no cardiac symp-toms, 
wild-type transthyretin may occasionally be deposited 
in massive amounts in the heart. When this occurs, 
congestive heart failure occurs and senile cardiac 
amyloidosis is found to be present [15]. 
Dialysis-Related Amyloidosis 
Is associated with deposition of beta-2 
microglobulin, which accumulate in patients with end-
stage renal disease, who are being treated with 
dialysis. 
In conclusion, cardiac amyloidosis, is a serious 
disease with a poor prognosis. The clinical cardiologist, 
should suspect cardiac amyloidosis in a patient, with 
symptoms of right heart failure and walls of left 
ventricle with restrictive pattern of diastolic dysfunction, 
coupled with low dynamic ECG. issue biopsy 
(subcutaneous fat pad biopsy, bone marrow biopsy), 
will put the final diagnosis. 
ABBREVIATIONS 
primary amyloidosis (AL), secondary amyloidosis 
(AA), monoclonal gammopathy of undetermined 
significance (MGUS), autologous stem cell 
transplantation (ASCT), systemic senile amyloidosis 
(SSA), transthyretin (TTR), proton-pump inhibitors 
(PPIs), stem cell transplantation (STC). 
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